Results 31 to 40 of about 9,047 (170)
Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components. [PDF]
Clin Pharmacol Drug DevAbstract Co‐administration of atorvastatin and fenofibrate has demonstrated clinical benefits in patients with dyslipidemia. To improve convenience and adherence, a fixed‐dose combination (FDC) of the two agents has gained interest. This study aimed to compare the pharmacokinetics (PKs) and safety of an FDC of atorvastatin/fenofibrate 20/145 mg with ...
Lee S +6 more
europepmc +2 more sources
PharmaceuticsEnterohepatic circulation (EHC) is a complex process where drugs undergo secretion and reabsorption from the intestinal lumen multiple times, resulting in pharmacokinetic profiles with multiple peaks.
Melchor Alpízar +4 more
doaj +1 more source
Frontiers in PharmacologyPhenytoin is a first-line antiepileptic drug with narrow therapeutic range and follows non-linear pharmacokinetics. Pharmacokinetics of phenytoin have been studied in plasma matrix before, however, there were several disadvantages.
Yahdiana Harahap +3 more
doaj +1 more source
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
British Journal of Clinical Pharmacology, EarlyView.Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog +8 more
wiley +1 more source
Low‐intervention clinical trials in Spain: Do they progress?
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza +4 more
wiley +1 more source
Pharmaceutics, 2023 Pilot bioavailability/bioequivalence (BA/BE) studies are downsized trials that can be conducted prior to the definitive pivotal trial. In these trials, 12 to 18 subjects are usually enrolled, although, in principle, a sample size is not formally ...
Sara Carolina Henriques +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia +3 more
wiley +1 more source
Journal of NanobiotechnologyThe blood–brain barrier (BBB) represents a formidable challenge in the treatment of neurological disorders, as it restricts the passage of most therapeutic agents into the central nervous system (CNS).
Suyi Liu +9 more
doaj +1 more source
MicroRNA: unveiling novel mechanistic and theranostic pathways in diabetic cardiomyopathy
Frontiers in PharmacologyDiabetic cardiomyopathy (DCM) is a prominent contributor to morbidity and mortality in people with diabetes worldwide. In diabetic patients, it is a chronic condition that is characterized by ventricular hypertrophy (VH), diastolic dysfunction ...
Akash De +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.The European Medicines Regulatory Network plays a critical role in safeguarding public health through the assessment and supervision of human medicines. However, rapid scientific and technological advancements have exposed capability deficits across the network, threatening timely and effective regulatory decision‐making.
Naomi Beard +4 more
wiley +1 more source